 | Up a level |
Journal Article
Hoemberg, M., Alakus, H. and Decarolis, B. (2022). Oncolytic Virus as a Therapeutic Approach in childhood diffuse intrinsic Pontine Glioma (DIPG). Onkologie, 28 (12). S. 1117 - 1119. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234
Hoemberg, M., Alakus, H. and Decarolis, B. (2022). SARS-CoV-2 in children with cancer. Onkologe, 28 (2). S. 164 - 166. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Homberg, M., Landgraf, P., Decarolis, B., Alakus, H. and Bruns, C. J. (2020). Factors influencing parental Grief after Death of a Child from Cancer. Onkologe, 26 (4). S. 371 - 373. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2017). I-131-mIBG therapy in high-risk neuroblastoma patients at end of induction chemotherapy. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S772 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2016). I-131-meta-iodobenzylguanidine therapy improves survival in high-risk neuroblastoma patients with I-123-mIBG positive residual metastatic disease. Eur. J. Nucl. Med. Mol. Imaging, 43. S. S31 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Simon, T., Schmidt, M., Decarolis, B., Eggert, A., Berthold, F. and Hero, B. (2017). I-131-Meta-Iodobenzylguanidine (MIBG) Therapy Improves Survival in High-Risk Neuroblastoma Patients with MIBG Positive Residual Metastatic Disease. Pediatr. Blood Cancer, 64. S. S33 - 2. HOBOKEN: WILEY. ISSN 1545-5017
van Wezel, E., Decarolis, B., Stutterheim, J., Zappeij-Kannegieter, L., Hero, B., Berthold, F., Simon, T., Schumacher-Kuckelkorn, R., van Noesel, M., Fiocco, M., Caron, H., van der Schoot, C. E. and Tytgat, G. (2015). MINIMAL BONE MARROW DISEASE IS FREQUENTLY DETECTED IN LOCALIZED NEUROBLASTOMA PATIENTS. Pediatr. Blood Cancer, 62. S. S226 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017